|
|
|
|
|
|
Sponsored by: |
Isis Pharmaceuticals |
Information provided by: | Isis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00330330 |
The aim of this study is to evaluate the safety, tolerability, and pharmacokinetics of five ISIS 113715 intravenous dose cohorts in drug-naïve type 2 diabetics.
Condition | Intervention | Phase |
Type 2 Diabetes Mellitus |
Drug: ISIS 113715 |
Phase II |
MedlinePlus related topics: | Diabetes |
ChemIDplus related topics: | Dextrose |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Activity of ISIS 113715 in Patients With Type 2 Diabetes Mellitus Who Have Not Received Prior Therapy |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Poland | |||||
Oddzial Chorob Wewnetrznych ze Stacja Dializ Szpital w Wolominie | |||||
Wolomin, Poland, 05-200 | |||||
NZOZ Specjalistyczny Osrodek Internistyczno Diabetologiczny | |||||
Bialystok, Poland, 15-435 | |||||
Prywatna Praktyka Lekarska | |||||
Radom, Poland, 26-600 | |||||
Russian Federation | |||||
Moscow Regional Scientific-Research Clinical Institute named after I.F. Vladimirsky | |||||
Moscow, Russian Federation, 129110 | |||||
Endocrinology Scientific Centre of RAMS | |||||
Moscow, Russian Federation, 117036 | |||||
Close Corporation "MEDSI" | |||||
Moscow, Russian Federation, 123056 | |||||
Chair of Endocrinology and Diabetology Central Clinical Hospital of the Ministry of Communications of RF | |||||
Moscow, Russian Federation, 125315 | |||||
Medical Institution "Polyclinic OAOA Gazprom" | |||||
Moscow, Russian Federation, 117420 | |||||
Clinic of Therapy of Postgraduate Education named after N.S. Molchanov | |||||
St. Petersburg, Russian Federation, 198013 | |||||
Chair of Endocrinology and Diabetology of the Faculty of Advenced Training for Physicians | |||||
Moscow, Russian Federation, 109125 |
Isis Pharmaceuticals |
Study Director: | Mark K Wedel, MD, JD, FACP | Isis Pharmaceuticals |
Study ID Numbers: | ISIS 113715-CS7 |
First Received: | May 24, 2006 |
Last Updated: | February 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00330330 |
Health Authority: | Russia: Pharmacological Committee, Ministry of Health |
|
|
|